About: Protection against homo and hetero-subtypic inﬂuenza A virus by optimized M2e DNA vaccine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Protection against homo and hetero-subtypic inﬂuenza A virus by optimized M2e DNA vaccine Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Protection against homo and hetero-subtypic inﬂuenza A virus by optimized M2e DNA vaccine
Creator	Chen, Jianjun Lan, Jiaming Chen, Ze Chen, Jie Chen, Quanjiao Shao, Zhiyong Wang, Huadong Yao, Yanfeng
Source	PMC
abstract	Current influenza vaccines provide hemagglutinin strain-specific protection, but rarely provide cross-protection against divergent strains. It is, therefore, particularly important to develop a universal vaccine against conserved proteins or conserved regions of the virus. In this study, we used N-terminal extracellular region of the influenza virus M2 protein (M2e) as the target antigen and constructed two optimized M2e DNA vaccines (p-tPA-p3M2e and p-p3M2e) with increased antigenic epitope density and enhanced antigen secretion. Both vaccines induced high M2e-specific humoral and cellular immune responses in the vaccinated mice. These two vaccines also conferred protection against a lethal infection of homo-subtypic H1N1 virus, with p-tPA-p3M2e being the most effective. In addition, p-tPA-p3M2e also showed cross-protection against different subtypes of the influenza virus (H9N2, H6N6, and H10N8) at varying rates (80%, 40%, and 20%, respectively). After passive immunization, M2e DNA vaccine-induced antibodies in the sera provided complete protection against homologous virus challenge. An analysis of the mechanism underlying this immunization-mediated protection indicates that M2e-specific IgG and T-cell immune responses may play critical roles in the prevention of infection and viral clearance. Taken together, our results indicate that this optimized M2e DNA vaccine is a promising candidate for the development of a universal, broad-spectrum influenza virus vaccine.
has issue date	2019-01-16(xsd:dateTime)
bibo:doi	10.1080/22221751.2018.1558962
bibo:pmid	30866759
has license	cc-by
sha1sum (hex)	766f315970750baecd98b7fcc1a0ba8d7368d1cc
schema:url	https://doi.org/10.1080/22221751.2018.1558962
resource representing a document's title	Protection against homo and hetero-subtypic inﬂuenza A virus by optimized M2e DNA vaccine
has PubMed Central identifier	PMC6455129
has PubMed identifier	30866759
schema:publication	Emerg Microbes Infect
resource representing a document's body	covid:766f315970750baecd98b7fcc1a0ba8d7368d1cc#body_text
is schema:about of	named entity 'complete' named entity 'Both' named entity 'virus' named entity 'M2E' named entity 'M2E' named entity 'RESULTS' named entity 'INCREASED' named entity 'RATES' named entity 'IMMUNIZATION' named entity 'UNDERLYING' named entity 'DIFFERENT' named entity 'DNA VACCINE' named entity 'CROSS' named entity 'EFFECTIVE' named entity 'INFLUENZA VIRUS VACCINE' named entity 'ROLES' named entity 'IMMUNE RESPONSES' named entity 'LETHAL INFECTION' named entity 'ANALYSIS' named entity 'MECHANISM' named entity 'DNA VACCINES' named entity 'H1N1' named entity 'PROTEIN ' named entity 'SUBTYPES' named entity 'TARGET' named entity 'CELLULAR' named entity 'SPECTRUM' named entity 'SPECIFIC' named entity 'ANTIGEN' named entity 'ANTIBODIES' named entity 'REGIONS' named entity 'STRAINS' named entity 'CONSTRUCTED' named entity 'STUDY' named entity 'USED' named entity 'STRAIN' named entity 'IGG' named entity '28P' named entity 'BUT' named entity 'M2 PROTEIN' named entity 'PLAY' named entity 'HEMAGGLUTININ' named entity 'IMPORTANT' named entity 'VACCINATED' named entity 'INFLUENZA VIRUS' named entity 'HOMO' named entity 'EXTRACELLULAR REGION' named entity 'RARELY' named entity 'EPITOPE' named entity 'HOMOLOGOUS' named entity 'T-CELL' named entity 'PREVENTION OF INFECTION' named entity 'PROVIDE' named entity 'INFLUENZA VACCINES' named entity 'SECRETION' named entity 'CANDIDATE' named entity 'VACCINE' named entity 'BEING' named entity 'PROTECTION' named entity 'INFLUENZA A VIRUS' named entity 'CURRENT' named entity 'MICE' named entity 'DEVELOPMENT' named entity 'INDUCED' named entity 'CONSERVED' named entity 'VIRAL CLEARANCE' named entity 'CRITICAL' named entity 'SERA' named entity '20%' named entity 'PASSIVE IMMUNIZATION' named entity 'TAKEN' named entity 'ENHANCED' named entity 'DENSITY' named entity 'PROTECTION'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software